ReviewTranslational breast cancer research : a journal focusing on translational research in breast cancer2025
Escalation and optimisation of primary breast cancer treatment with antibody-drug conjugates.
Review in Translational breast cancer research : a journal focusing on translational research in breast cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A Pyrone Glucoside fromBiomolecules · 2026Article
- Selective real-time disulfide reduction with simultaneous fluorescent labeling of a humanized anti-cocaine mAb.Biochemistry and biophysics reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibody-drug conjugates (ADCs) have become the standard of care for metastatic advanced breast cancers, regardless of tumour subtype. Optimal positioning and treatment sequences are being studied, and many new therapies and combinations are also under development. Research into the application of ADC to early breast cancer is spreading. More than 10 clinical trials are being conducted regarding escalation and de-escalation of systemic treatment. In addition, in the sequence of neoadjuvant and adjuvant therapy, multiple key issues are investigated, such as effective sequences of treatments among ADC, cytotoxic chemotherapy, immunotherapy, and anti-human epidermal growth factor receptor 2 antibody therapy to improve treatment response, prognosis and quality of life (QOL). The postoperative activity of ADC with topoisomerase inhibitors for residual diseases is also being studied in post-neoadjuvant therapy settings. At the same time, many studies have focused on the appropriate timing of surgical therapy and response-guided approach. On the other hand, ADCs can cause serious side effects, although these are infrequent. Therefore, careful management is necessary during both pre-operative and post-operative adjuvant therapy. It is also crucial to focus on developing prognostic and predictive biomarkers to assess efficacy, alongside monitoring markers through translational research and image analysis. This review summarizes the development trends in both neoadjuvant and adjuvant settings, as well as recent data on ADCs for primary breast cancer, while addressing unresolved clinical questions. It discusses the escalation and optimization of treatment for primary breast cancer using ADCs, along with the relevant challenges and perspectives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.